Looking for more information on the ongoing ADAPT Phase 3 clinical trial in MG? Click here.

Contact

Please contact us if you have any IR related questions:

Send

Joke Comijn
Investor Relations Manager
+32 9 241 58 41
jcomijn@argenx.com